Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2020-07-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于公司分拆所属子公司华兰生物疫苗股份有限公司至创业板上市之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" issued by Huatai United Securities Co., Ltd. regarding the spin-off and listing of a subsidiary (Hualan Biological Vaccine Co., Ltd.) on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). The document extensively discusses compliance with regulatory requirements, legal and financial due diligence, audit reports, and the independent financial advisor's conclusions on the spin-off's legality, benefits, and compliance. It is a detailed advisory and verification report related to a capital restructuring event involving a subsidiary's IPO. This type of document is not a general annual report, earnings release, or management discussion but a specialized advisory opinion related to a capital/financing event (spin-off and listing). Therefore, the most appropriate classification is "Capital/Financing Update (CAP)". The document length (12,295 characters) and content confirm it is a full advisory report, not a brief announcement or certification, so it is not RPA or RNS. Confidence is high given the detailed financial and legal analysis and the nature of the document as an independent financial advisor's opinion on a capital restructuring event.
2020-07-10 Chinese
第七届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 7th Board of Directors of 华兰生物工程股份有限公司. It discusses the approval of a plan to spin off a subsidiary (华兰生物疫苗股份有限公司) for listing on the Shenzhen Stock Exchange's ChiNext board. The document includes detailed legal and regulatory compliance information, voting results, and procedural authorizations related to the spin-off and listing process. It also mentions changes in securities affairs representatives and the scheduling of an extraordinary shareholders meeting. The content is focused on board meeting decisions and management-level approvals rather than a full financial report, audit report, or earnings release. It is not a transcript of a call, nor a proxy solicitation or voting results announcement. The document is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length (over 10,000 characters) and detailed content confirm it is not a brief announcement or report publication notice.
2020-07-10 Chinese
关于公司分拆所属子公司华兰生物疫苗股份有限公司至深圳证券交易所创业板上市的专项核查说明
Audit Report / Information Classification · 95% confidence The document is a detailed special verification report issued by a certified public accounting firm regarding the spin-off and listing of a subsidiary company (华兰生物疫苗股份有限公司) on the Shenzhen Stock Exchange ChiNext board. It references compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, discusses financial metrics over multiple years, independence of management, and absence of conflicts or related party transactions. The document includes audit opinions and detailed compliance checks but is not a full annual or interim financial report. It is a specialized audit verification report related to a capital market transaction (spin-off and listing). This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report verifying compliance and financial conditions for a specific transaction, not a full annual report or earnings release. The document length (6619 characters) and content confirm it is a substantive audit verification report, not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2019
2020-07-10 Chinese
安徽承义律师事务所关于公司分拆华兰生物疫苗股份有限公司至深圳证券交易所创业板上市的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the spin-off and listing of a subsidiary company (华兰生物疫苗股份有限公司) from the parent company (华兰生物工程股份有限公司) on the Shenzhen Stock Exchange's Growth Enterprise Market. It extensively discusses compliance with relevant laws and regulations, board resolutions, audit reports, and conditions for the spin-off. The document is a detailed legal opinion related to a corporate restructuring and listing transaction, not a financial report, earnings release, or management discussion. It is not a proxy statement, voting result, or remuneration report. It is a legal proceeding or advisory document related to a significant corporate transaction (spin-off and listing). Therefore, it fits best under Legal Proceedings Report (LTR).
2020-07-10 Chinese
第七届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 7th Supervisory Board of 华兰生物工程股份有限公司. The content focuses on the approval and discussion of the plan to spin off a subsidiary (华兰生物疫苗股份有限公司) for listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes legal compliance, financial audit references, corporate governance, independence, and related party transactions. The document is a formal announcement of board resolutions rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis but rather decisions and approvals related to corporate actions and compliance. The document length is 9270 characters, which is substantial but the content is clearly a meeting resolution announcement. Therefore, the document fits best into the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management, including resolutions passed in board or supervisory meetings.
2020-07-10 Chinese
独立董事关于第七届董事会第十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's board meeting, specifically regarding the spin-off listing of a subsidiary and the transfer of patents. It references the board meeting (seventh board, tenth meeting) and provides independent opinions on these corporate governance matters. The content focuses on governance and compliance with laws and regulations, rather than financial results or audit findings. It is not a full annual or interim report, nor an earnings release or audit report. It is not a simple announcement but a detailed opinion from independent directors on board matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and management.
2020-07-10 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.